ABSTRACT
The developing resistance of microorganisms to the effects of antibacterial drugs creates difficulties in the treatment of purulent diseases. This is especially reasonable in the pandemic of a new coronavirus infection (COVID-19). The aggressive effect of new strains of the virus on the mucous membrane of the nasal cavity and nasopharynx contributes to the occurrence of complications such as acute purulent otitis media and exacerbation of chronic purulent otitis, both during coronavirus infection and in the postcovid period. Even before the start of the pandemic, antibiotic resistance was already one of the big problems in most countries of the world, this was due to the frequent unjustified appointment of systemic antibacterial agents for viral infection, as well as uncontrolled self-medication of the population with all available drugs. Due to the fear of people getting sick with COVID-19 and disagreements among doctors in treatment tactics, the use of systemic antibiotics and hor-monal drugs increased already in the first months of the pandemic. In the future, the unjustifiability of this tactic was proved, but many doctors continued to prescribe several systemic antibacterial drugs to patients with uncomplicated viral infection. Under the current conditions, when there is evidence of bacterial infection, it is rational to use local antibacterial drugs, which allows you to quickly reach high concentrations in the focus of inflammation and avoid side effects of systemic antibiotics. Among the existing means in the complex therapy of perforated otitis, a special place belongs to the preparations of the group of quinoxaline derivatives, which include hydroxymethylquinoxalindioxide (Dioxidine). The advantage of the drug is its effectiveness against resistant microorganisms, as well as stimulation of marginal tissue regeneration. This property is especially important in the treatment of perforated otitis media. © 2022, Remedium Group Ltd. All rights reserved.
ABSTRACT
In the pandemic new coronavirus infection (COVID-19), different clinical symptoms are observed depending on its dominant strain. The Omicron strain affects the nasal mucosa, causing the possibility of complications such as tubootitis and acute otitis media. Untimely or incomplete treatment of otitis media can contribute to the development of chronic forms of the course. Inflammatory process in the middle ear always proceeds with impaired hearing function due to the development of adhesions in the tympanic cavity. In patients with a reduced immune status, weakened course of the coronavirus infection itself, recovery comes later with a long recovery of hearing acuity, so it is very important to start treatment at the first manifestations of pain in the ear. In addition, the danger of otitis media against the background of SARS-CoV-2, if not treated in time, is the development of serious complications – mastoiditis, meningeal syndrome. Local analgesic therapy in the form of analgesic ear drops is recommended to reduce inflammation of the eardrum tissues. The combination of phenazone and lidocaine allows you to quickly stop the pain, block the development of phases of inflammation in the middle ear. Using a combination of phenazone and lidocaine reduces the time of onset of the analgesic effect, while increasing the intensity and duration of action, which is very important, especially in children. These components are not resorbed and have no systemic effect on the patient’s body. The combination of phenazone and lidocaine can be used in the treatment of children of all age groups, adults, pregnant women and nursing mothers. © 2022, Remedium Group Ltd. All rights reserved.